Corrigendum to “Selective binding of C-6OH sulfated hyaluronic acid to the angiogenic isoform of VEGF165” [Biomaterials 77(2016) 130–138, (S0142961215008844), (10.1016/j.biomaterials.2015.10.074)];Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF165

Biomaterials

Volumn 77, Issue , 2016, Pages 130-138

  Lim, Dong Kwon ^a,d   Wylie, Ryan G ^b,d   Langer, Robert ^c   Kohane, Daniel S ^d  

^a Korea University   (South Korea)

^b MCMASTER UNIVERSITY   (Canada)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Selective binding property; Sulfated sodium hyaluronate; Vascular endothelial growth factor 165; VEGF165a; VEGF165b

Indexed keywords

ANTIBODIES; BINDING ENERGY; CELL ENGINEERING; COST EFFECTIVENESS; DISEASES; DISSOCIATION; DRUG DELIVERY; ENDOTHELIAL CELLS; ORGANIC ACIDS; SULFUR COMPOUNDS; SYNTHESIS (CHEMICAL);

ANGIOGENESIS; BINDING PROPERTIES; SELECTIVE BINDING; SELECTIVE BINDING PROPERTY; SODIUM HYALURONATE; SULPHATED SODIUM HYALURONATE; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR 165; VEGF165A; VEGF165B;

HYALURONIC ACID;

BEVACIZUMAB; BIOMATERIAL; BIOPOLYMER; C 6 HYDROXYL; COUNTERION; HYALURONIC ACID DERIVATIVE; HYDROXYL GROUP; N ACETYLGLUCOSAMINE; PYRIDINE; SULFATED HYALURONIC ACID; TETRABUTYLAMMONIUM; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN 165A; VASCULOTROPIN 165B; ANGIOGENESIS INHIBITOR; C-6 OH SULFATED HYALURONIC ACID; CHONDROITIN SULFATE; HYALURONIC ACID; PROTEIN BINDING; RECOMBINANT PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSOCIATION RATE CONSTANT; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DISSOCIATION RATE CONSTANT; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; SULFATION; SURFACE PLASMON RESONANCE; UMBILICAL VEIN ENDOTHELIAL CELL; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; CONFORMATION; DRUG EFFECTS; ENZYME SPECIFICITY; KINETICS; METABOLISM; MOLECULAR GENETICS; PRECLINICAL STUDY; PROTEIN TERTIARY STRUCTURE; SYNTHESIS;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CARBOHYDRATE CONFORMATION; CHONDROITIN SULFATES; DRUG EVALUATION, PRECLINICAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYALURONIC ACID; KINETICS; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84949256478     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2024.122501     Document Type: Erratum

References (36)

1. Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat. Med. 2010, 16:1107-1111.
2. Witmer A.N., Vrensen G., Van Noorden C.J.F., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin Eye Res. 2003, 22:1-29.
3. Folkman J., Langer R., Linhardt R.J., Haudenschild C., Taylor S. Angiogenesis inhibition and tumor-regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983, 221:719-725.
4. Folkman J., Bach M., Rowe J.W., Davidoff F., Lambert P., Hirsch C., et al. Tumor angiogenesis - therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
5. Andreoli C.M., Miller J.W. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr. Opin. Ophthalmol. 2007, 18:502-508.
6. Ng E.W., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006, 5:123-132.
7. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69:11-16.
8. Bates D.O., Cui T.G., Doughty J.M., Winkler M., Sugiono M., Shields J.D., et al. VEGF(165)b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002, 62:4123-4131.
9. Nowak D.G., Woolard J., Amin E.M., Konopatskaya O., Saleem M.A., Churchill A.J., et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J. Cell Sci. 2008, 121:3487-3495.
10. Woolard J., Wang W.Y., Bevan H.S., Qiu Y., Morbidelli L., Pritchard-Jones R.O., et al. VEGF(165)b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004, 64:7822-7835.
11. Magnussen A.L., Rennel E.S., Hua J., Bevan H.S., Long N.B., Lehrling C., et al. VEGF-A165b Is cytoprotective and Antiangiogenic in the Retina. Investig. Ophthalmol. Vis. Sci. 2010, 51:4273-4281.
12. Willis J., Scott R., Darlow B., Campbell-Stokes P.L., Taylor B.J. Prospective incidence study of diabetes mellitus in New Zealand children aged 0 to 14 years. Diabetologia 48: 643-648. Diabetologia 2005, 2005(48):2442-2443. on behalf of the New Zealand Children's Diabetes Working Group.
13. Varey A., Rennel E., Qiu Y., Bevan H., Perrin R., Raffy S., et al. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy. Br. J. cancer 2008, 98:1366-1379.
14. Robinson C.J., Mulloy B., Gallagher J.T., Stringer S.E. VEGF(165)-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J. Biol. Chem. 2006, 281:1731-1740.
15. Harper S.J., Bates D.O. VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat. Rev. Cancer 2008, 8:880-887.
16. Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. BBA Proteins Proteom. 2010, 1804:567-580.
17. Dejima K., Kleinschmit A., Takemura M., Choi P.Y., Kinoshita-Toyoda A., Toyoda H., et al. The role of drosophila heparan sulfate 6-O-endosulfatase in sulfation compensation. J. Biol. Chem. 2013, 288:6574-6582.
18. Magnussen A.L., Rennel E.S., Hua J., Bevan H.S., Long N.B., Lehrling C., et al. VEGF-A165b is cytoprotective and antiangiogenic in the retina. Investig. Ophthalmol. Vis. Sci. 2010, 51:4273-4281.
19. Benitez A., Yates T.J., Lopez L.E., Cerwinka W.H., Bakkar A., Lokeshwar V.B. Targeting hyaluronidase for cancer therapy: Antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res. 2011, 71:4085-4095.
20. Cole C.L., Hansen S.U., Barath M., Rushton G., Gardiner J.M., Avizienyte E., et al. Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis. PLoS One 2010, 5.
21. Hacker U., Nybakken K., Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat. Rev. Mol. Cell Biol. 2005, 6:530-541.
22. Hintze V., Moeller S., Schnabelrauch M., Bierbaum S., Viola M., Worch H., et al. Modifications of hyaluronan influence the interaction with human bone morphogenetic protein-4 (hBMP-4). Biomacromolecules 2009, 10:3290-3297.
23. Chang N.S., Intrieri C., Mattison J., Armand G. Synthetic polysulfated hyaluronic acid is a potent inhibitor for tumor necrosis factor production. J. Leukoc. Biol. 1994, 55:778-784.
24. Chang N.-S. Hyaluronidase induces murine L929 fibrosarcoma cells resistant to tumor necrosis factor and fas cytotoxicity in the presence of actinomycin D. Cell Biochem. Biophys. 1995, 27:109-132.
25. Magnani A., Lamponi S., Rappuoli R., Barbucci R. Sulphated hyaluronic acids: a chemical and biological characterisation. Polym. Int. 1998, 46:225-240.
26. Schasfoort R.B., Tudos A.J. Handbook of Surface Plasmon Resonance 2008, Royal Society of Chemistry.
27. Maynard H.D., Hubbell J.A. Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. Acta Biomater. 2005, 1:451-459.
28. Hoshino Y., Nakamoto M., Miura Y. Control of protein-binding kinetics on synthetic polymer nanoparticles by tuning flexibility and inducing conformation changes of polymer chains. J. Am. Chem. Soc. 2012, 134:15209-15212.
29. Nishiguchi K.M., Kataoka K., Kachi S., Komeima K., Terasaki H. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS One 2010, 5:e13493.
30. Muller Y.A., Chen Y., Christinger H.W., Li B., Cunningham B.C., Lowman H.B., et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface. Structure 1998, 6:1153-1167.
31. Lee J.-H., Canny M.D., De Erkenez A., Krilleke D., Ng Y.-S., Shima D.T., et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18902-18907.
32. Yamazaki K., Nagao T., Yamaguchi T., Saisho H., Kondo Y. Expression of basic fibroblast growth factor (FGF-2)-associated with tumour proliferation in human pancreatic carcinoma. Virchows Arch. 1997, 431:95-101.
33. Klettner A., Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Investiga. Ophthalmol. Vis. Sci. 2008, 49:4523.
34. Nishiguchi K.M., Kataoka K., Kachi S., Komeima K., Terasaki H. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS One 2010, 5.
35. Taipale J., Keski-Oja J. Growth factors in the extracellular matrix. FASEB J. 1997, 11:51-59.
36. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. biophys. Res. Commun. 2005, 333:328-335.